Key Findings:  This case report documents a 55-year-old with multiple sclerosis (MS) who, after 4 weeks of adjuvant Sativex, developed behavioral changes, including suicidal ideation. While causation was not clearly established, it does raise concern over concomitant use of cannabinoid products with baclofen and methylprednisolone for MS.
Type of Study:  Meta-analysis
Study Sample Size:  1
Study Result:  Negative
Research Location(s):  Italy
Year of Pub:  2015
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Pharma THC:CBD
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype II
Route of Administration:  Sublingual/Oromucosal
Citation:  Russo M, Rifici C, Sessa E, D'Aleo G, Bramanti P, Calabrò RS. Sativex-induced neurobehavioral effects: causal or concausal? A practical advice! Daru. 2015 Apr 17;23(1):25. doi: 10.1186/s40199-015-0109-6. PMID: 25881038; PMCID: PMC4407789.